3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma

NCT01183429 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Neuroblastoma

Interventions

DRUG: 3F8 and 13-cis-retinoic acid

Sponsor

Memorial Sloan Kettering Cancer Center